In the first study, the authors showed that apigenin mitigated HFD-induced non-alcoholic fatty liver disease (NAFLD) progression, attenuating lipid accumulation and oxidative stress in mice; these effects were mainly attributed to the ability of apigenin to activate Nrf2 by promoting its translocation into the nucleus that, in turn, inhibited the function of PPARγ [156]. The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatotic liver disease.